Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 143Neoplasm Metastasis 16Ovarian Neoplasms 6Advanced Breast Cancer 6Prostatic Neoplasms 5Breast Cancer Metastatic 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Lobular 3Lung Neoplasms 2HER2-positive Breast Cancer 2Exanthema 2Estrogen Receptor-positive Breast Cancer 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1The Neoadjuvant Therapy 1Stomach Neoplasms 1Solid Tumor 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Sarcoma 1Salivary Gland Neoplasms 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Malignant Neoplasms of Female Genital Organs 1

Interventions

Everolimus 5Temozolomide 4sargramostim 2montanide ISA 51 2lutetium Lu 177 dotatate 2incomplete Freund's adjuvant 2Sunitinib 2Specimen Handling 2Sorafenib 2Octreotide 2Magnetic Resonance Spectroscopy 2Leucovorin 2Fluorouracil 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1nimotuzumab 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1cabozantinib 1atezolizumab 1abemaciclib 1Wound Healing 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Islet Cell × Fulvestrant × Clear all
NCT06663072 2026-01-09

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

University of Chicago

Phase 1 Recruiting
25 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡